Anatomic Stage IIIA Breast Cancer AJCC v8 Terminated Phase 1 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0109626 (Anatomic Stage IIIA Breast Cancer AJCC v8)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04185311Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedTreatment